The present application provides pyrrolotriazine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

The present invention relates to saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds, or pharmaceutically acceptable salts having RORγ antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula [I] or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided: ##STR00001## wherein each substituent is defined as defined in the description.

The present disclosure relates to an organic compound and an organic light emitting display device using the same wherein the organic compound is represented by Chemical Formula 1 and a display device using the organic compound. The organic compound represented by Chemical Formula 1 has excellent electron transport properties and durability and is used for an electron transport layer of an organic light emitting element, thereby lowering a driving voltage and improving the luminous efficiency and lifetime.

##STR00001##

(In the above Chemical Formula 1, at least two of X.sub.1, X.sub.2 and X.sub.3 are N, Y.sub.1 and Y.sub.2 are each independently a substituted or unsubstituted phenylene group or a single bond, at least one of Ar.sub.1 and Ar.sub.2 is selected from a substituted or unsubstituted triazine group, a functional group represented by Chemical Formula 2 and a functional group represented by Chemical Formula 3.)

The present disclosure relates to an organic compound and an organic light emitting display device using the same wherein the organic compound is represented by Chemical Formula 1 and a display device using the organic compound. The organic compound represented by Chemical Formula 1 has excellent electron transport properties and durability and is used for an electron transport layer of an organic light emitting element, thereby lowering a driving voltage and improving the luminous efficiency and lifetime.

##STR00001##

(In the above Chemical Formula 1, at least two of X.sub.1, X.sub.2 and X.sub.3 are N, Y.sub.1 and Y.sub.2 are each independently a substituted or unsubstituted phenylene group or a single bond, at least one of Ar.sub.1 and Ar.sub.2 is selected from a substituted or unsubstituted triazine group, a functional group represented by Chemical Formula 2 and a functional group represented by Chemical Formula 3.)

A method of treating a disorder. The method includes administering to a subject in need thereof a compound of general formula (I): ##STR00001##
Each of A, N*, X, Y, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

A method of treating a disorder. The method includes administering to a subject in need thereof a compound of general formula (I): ##STR00001##
Each of A, N*, X, Y, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

Benzotriazine doxides are disclosed as drugs targeting mycobacterium tuberculosis, including novel compounds of formula I:

##STR00001##

Benzotriazine doxides are disclosed as drugs targeting mycobacterium tuberculosis, including novel compounds of formula I:

##STR00001##

Benzotriazine doxides are disclosed as drugs targeting mycobacterium tuberculosis, including novel compounds of formula I: ##STR00001##

Benzotriazine doxides are disclosed as drugs targeting mycobacterium tuberculosis, including novel compounds of formula I: ##STR00001##